检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:覃玉桃[1] 康敏[1] 张勇[1] 刘文其[1] 王仁生[1]
机构地区:[1]广西医科大学第一附属医院放疗科,南宁530021
出 处:《中国癌症防治杂志》2013年第2期148-151,共4页CHINESE JOURNAL OF ONCOLOGY PREVENTION AND TREATMENT
基 金:广西医疗卫生重点科研课题(重200626)
摘 要:目的观察放化疗联合热疗治疗鼻咽癌颈部淋巴结转移的疗效。方法将203例初治的鼻咽癌颈部淋巴结转移患者随机分为对照组(98例)和热放组(105例)。对照组接受5-氟尿嘧啶+顺铂诱导化疗后对鼻咽原发灶和颈部淋巴结转移灶予以常规放疗。热放组放化疗方法同对照组,颈部淋巴结转移灶于放疗第1周开始配合局部热疗。结果热放组和对照组治疗后3个月颈部淋巴结转移灶的完全消退率分别为81.0%和62.2%(P<0.05),5年无瘤生存率分别为51.4%和20.4%(P<0.05),3年生存率和5年生存率分别为76.2%、52.0%和58.1%、40.8%(P均<0.05)。两组湿性皮炎的发生率分别为5.7%和3.1%(P>0.05)。结论放化疗联合热疗治疗鼻咽癌颈部淋巴结转移的近期疗效、远期疗效均优于单纯放化疗。Objective To evaluate the effect of combined chemotherapy-radiotherapy-hyperthermia on patients with nasopharyngeal carcinoma and cervical lymph node metastasis. Methods A total of 203 cases of nasopharyngeal carcinoma with cervical lymph node metastasis were randomly divided into two groups:the control group(98 cases),which was treated with combined 5-fluorouracil and cisplatin chemotherapy, as well as routine radiotherapy; and the hyperthermia group( 105 cases),which was treated with the same chemo- and radiotherapy as the control group to treat nasopharyngeal careinoma,while cervical lymph node metastasis was treated with hyperthermia accompanied by radiotherapy. Results Complete response rates of cervical lymph nodes were 62.2% in the control group and 81.0% in the hyperthermia group (P〈0.05).The 5 year disease-free survival rates was 20.4% in the control group and 51.4% in the hyperthermia group (P〈0.05).The 3- and 5-year overall survival rate were 52.0% and 40.8% in the control group and 76.2% and 58.1% in the hyperthermia group (P〉0.05). Conclusions The combination of ehemotherapy-radiotherapy-hyperthermia is more effective than chemotherapy-radiotherapy for patients with nasopharyngeal carcinoma and cervical lymph node metastasis.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.158